Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NRIX +2.8%
Other news:
- IVA +70.4% (announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study)
- LBPH +50.6% (to be acquired by Lundbeck (HLUYY) for $60.00 per share in cash)
- JSPR +25.8% (reports preliminary data from the Company's ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab)
- RILY +17.8% (establishes partnership with Oaktree in the Great American Group Businesses)
- BLCO +8.7% (Blackstone (BX) and TPG considering joint bid for BLCO, according to FT; receives FDA approval for full range of enVista Envy)
- SUUN +8.4% (plans 7-Megawatt Solar Project in Development by SolarBank in Pennsylvania)
- VNDA +8.3% (Cycle Pharmaceuticals mulling acquisition of VNDA, according to Bloomberg)
- VRA +6.9% (Board of Directors unanimously approves the adoption of a limited duration shareholder rights to guard against "abusive tactics so that no person, entity or group can gain a control or control-like postion")
- RDHL +5.6% (Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment)
- SIRI +3.9% (Berkshire Hathaway's (BRK.A / BRK.B) Warren Buffett bought 3,564,059 shares at $22.96 - $25.14 worth approx. $86.7 mln)
- RDW +3.2% (prepares for a major European satellite delivery in the fourth quarter as international customer demand increases)
- BNTC +2.7% (Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society)
- ODV +2.4% (closes final tranche of non-brokered private placement for total aggregate proceeds of $34.5 mln)
- GATO +1.6% (disclosed material elements of the Company's June 21, 2024 response to a comment letter issued by the SEC, dated June 6, 2024, relating to the SEC's review)
- NTRA +1.5% (positive Barron's article)
- TMHC +1% (positive Barron's article)